Table 2 Prior anti-migraine preventive therapies of patients (N = 70) in the study, showing pharmacological classes and corresponding reason for failure
Patients | No meaningful improvement | Adverse events | Treatment discontinuationa | |
|---|---|---|---|---|
Tricyclic antidepressants | 65 (93) | 55 (85) | 10 (15) | 48 (68) |
Beta-blockers | 63 (90) | 56 (88) | 7 (12) | 48 (68) |
Calcium channel blockers | 28 (40) | 22 (78) | 6 (12) | 25 (36) |
Topiramate | 62 (88) | 47 (76) | 15 (24) | 50 (71) |
Valproate | 15 (21) | 9 (60) | 6 (40) | 13 (18) |
OnabotulinumtoxinA | 54 (77) | 54 (100) | – | 49 (70) |